The pharmaceutical industry is opening a new line of attack against health insurers in the escalating battle over drug prices.
Global drug lobby the Biotechnology Innovation Organization (BIO) is accusing insurance companies of funneling cash into a little-known outside group that recommends its own drug prices with hopes of driving down overall costs.
The decade-old group, called the Institute of Clinical and Economic Review (ICER), has been hailed as a “Consumer Reports” for prescription drugs and is one of the only sources of drug data available to the public.
Read Full Article »